Pitavastatin fails to lower serum lipid levels or inhibit gastric carcinogenesis in Helicobacter pylori-infected rodent models

Cancer Prevention Research

Volumn 2, Issue 8, 2009, Pages 751-758

  Toyoda, Takeshi ^a   Tsukamoto, Tetsuya ^a   Takasu, Shinji ^a   Hirano, Naoki ^a   Ban, Hisayo ^a   Shi, Liang ^a   Kumagai, Toshiko ^c   Tanaka, Takuji ^d   Tatematsu, Masae ^a,b  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c SHINSHU UNIVERSITY HOSPITAL   (Japan)

^d KANAZAWA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; LOW DENSITY LIPOPROTEIN; MESSENGER RNA; METHYLNITROSOUREA; PITAVASTATIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFECT; GASTRITIS; GERBIL; HELICOBACTER INFECTION; LIPID BLOOD LEVEL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH ADENOCARCINOMA; STOMACH CARCINOGENESIS; TRIACYLGLYCEROL BLOOD LEVEL; UPREGULATION;

ANIMALS; CARCINOMA; DISEASE MODELS, ANIMAL; DOWN-REGULATION; ENZYME INHIBITORS; GERBILLINAE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; LIPIDS; MALE; MICE; MICE, INBRED C57BL; MODELS, BIOLOGICAL; QUINOLINES; RODENTIA; STOMACH NEOPLASMS; TREATMENT FAILURE;

EID: 77951122888     PISSN: 19406207     EISSN: None     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-09-0082     Document Type: Article

References (44)

1. Hebert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA 1997;278:313-321
2. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-1278
3. Dulak J, Jozkowicz A. Anti-angiogenic and anti-inflammatory effects of statins: relevance to anti-cancer therapy. Curr Cancer Drug Targets 2005;5:579-594 (Pubitemid 41789598)
4. Ito MK, Talbert RL, Tsimikas S. Statin-associated pleiotropy: possible beneficial effects beyond cholesterol reduction. Pharmacotherapy 2006;26:85-101S. (Pubitemid 43993553)
5. Poynter JN, Gruber SB, Higgins PD, et al. Statins and the risk of colorectal cancer. N Engl J Med 2005;352:2184-2192
6. Demierre MF, Higgins PD, Gruber SB, Hawk E, Lippman SM. Statins and cancer prevention. Nat Rev Cancer 2005;5:930-942
7. Chan KK, Oza AM, Siu LL. The statins as anticancer agents. Clin Cancer Res 2003;9:10-19
8. Coogan PF, Smith J, Rosenberg L. Statin use and risk of colorectal cancer. J Natl Cancer Inst 2007;99:32-40. (Pubitemid 46263361)
9. Browning DR, Martin RM. Statins and risk of cancer: a systematic review and metaanalysis. Int J Cancer 2007;120:833-843 (Pubitemid 46175404)
10. Dale KM, Coleman CI, Henyan NN, Kluger J, White CM. Statins and cancer risk: a meta-analysis. JAMA 2006;295:74-80.
11. Jacobs EJ, Rodriguez C, Brady KA, Connell CJ, Thun MJ, Calle EE. Cholesterol-lowering drugs and colorectal cancer incidence in a large United States cohort. J Natl Cancer Inst 2006;98:69-72. (Pubitemid 43057094)
12. Vinogradova Y, Hippisley-Cox J, Coupland C, Logan RF. Risk of colorectal cancer in patients prescribed statins, nonsteroidal anti-inflammatory drugs, and cyclooxygenase-2 inhibitors: nested case-control study. Gastroenterology 2007;133:393-402. (Pubitemid 47187349)
13. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
14. Yasui Y, Suzuki R, Miyamoto S, et al. A lipophilic statin, pitavastatin, suppresses inflammation-associated mouse colon carcinogenesis. Int J Cancer 2007;121:2331-2339 (Pubitemid 47585616)
15. Swamy MV, Patlolla JM, Steele VE, Kopelovich L, Reddy BS, Rao CV. Chemoprevention of familial adenomatous polyposis by low doses of atorvastatin and celecoxib given individually and in combination to APCMin mice. Cancer Res 2006;66:7370-7377 (Pubitemid 44197721)
16. Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001;345:784-789
17. IARC Working Groupon the Evaluation of Carcinogenic Risks to Humans Infection with Helicobacter pylori. Schistosomes, liver flukes and Helicobacter pylori. In: IARC monographs on the evaluation of carcinogenic risks to humans, vol. 61. Lyon: World Health Organization/International Agency for Research on Cancer; 1994. p. 177-241.
18. Patel P, Mendall MA, Carrington D, et al. Association of Helicobacter pylori and Chlamydia pneumoniae infections with coronary heart disease and cardiovascular risk factors. BMJ 1995;311:711-714
19. Niemela S, Karttunen T, Korhonen T, et al. Could Helicobacter pylori infection increase the risk of coronary heart disease by modifying serum lipid concentrations? Heart 1996;75:573-575
20. Sugiyama A, Maruta F, Ikeno T, et al. Helicobacter pylori infection enhances N-methyl-N-nitrosourea-induced stomach carcinogenesis in the Mongolian gerbil. Cancer Res 1998;58:2067-2069 (Pubitemid 28232885)
21. Mukhtar RY, Reid J, Reckless JP. Pitavastatin. Int J Clin Pract 2005;59:239-252
22. Shimizu N, Inada KI, Tsukamoto T, et al. New animal model of glandular stomach carcinogenesis in Mongolian gerbils infected with Helicobacter pylori and treated with a chemical carcinogen. J Gastroenterol 1999;34:61-66 (Pubitemid 30072489)
23. Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996;20:1161-1181
24. Tanaka T, Kohno H, Suzuki R, et al. Dextran sodium sulfate strongly promotes colorectal carcinogenesis in Apc(Min/+) mice: inflammatory stimuli by dextran sodium sulfate results in development of multiple colonic neoplasms. Int J Cancer 2006;118:25-34. (Pubitemid 41681577)
25. Zingarelli B, Szabo C, Salzman AL. Reduced oxidative and nitrosative damage in murine experimental colitis in the absence of inducible nitric oxide synthase. Gut 1999;45:199-209. (Pubitemid 29333768)
26. Cao X, Tsukamoto T, Seki T, et al. 4-Vinyl-2,6-dimethoxyphenol (canolol) suppresses oxidative stress and gastric carcinogenesis in Helicobacter pylori-infected carcinogen-treated Mongolian gerbils. Int J Cancer 2008;122:1445-1454 (Pubitemid 351294952)
27. Tsukamoto T, Fukami H, Yamanaka S, et al. Hexosaminidase-altered aberrant crypts, carrying decreased hexosaminidase α and β subunit mRNAs, in colon of 1,2-dimethylhydrazine-treated rats. Jpn J Cancer Res 2001;92:109-118 (Pubitemid 32237088)
28. Karp I, Behlouli H, Lelorier J, Pilote L. Statins and cancer risk. Am J Med 2008;121:302-309
29. Kuoppala J, Lamminpaa A, Pukkala E. Statins and cancer: a systematic review and meta-analysis. Eur J Cancer 2008;44:2122-2132
30. Lubet RA, Boring D, Steele VE, Ruppert JM, Juliana MM, Grubbs CJ. Lack of efficacy of the statins atorvastatin and lovastatin in rodent mammary carcinogenesis. Cancer Prev Res 2009;2:161-167
31. Bhuket TP, Higgins PD. Drug insight: statins and gastrointestinal cancer. Nat Clin Pract Gastroenterol Hepatol 2006;3:552-562 (Pubitemid 44489588)
32. Moorman PG, Hamilton RJ. Statins and cancer risk: what do we know and where do we go from here? Epidemiology 2007;18:194-196
33. Saito Y, Yamada N, Teramoto T, et al. A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia. Atherosclerosis 2002;162:373-379 (Pubitemid 34457943)
34. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 2006;80:565-581 (Pubitemid 44908269)
35. Sakagami T, Dixon M, O'Rourke J, et al. Atrophic gastric changes in both Helicobacter felis and Helicobacter pylori infected mice are host dependent and separate from antral gastritis. Gut 1996;39:639-648 (Pubitemid 26426462)
36. Miyamoto S, Yasui Y, Kim M, et al. A novel rasH2 mouse carcinogenesis model that is highly susceptible to 4-NQO-induced tongue and esophageal carcinogenesis is useful for preclinical chemoprevention studies. Carcinogenesis 2008;29:418-426 (Pubitemid 351359683)
37. Cao X, Tsukamoto T, Nozaki K, et al. Severity of gastritis determines glandular stomach carcinogenesis in Helicobacter pylori-infected Mongolian gerbils. Cancer Sci 2007;98:478-483
38. Pasceri V, Cammarota G, Patti G, et al. Association of virulent Helicobacter pylori strains with ischemic heart disease. Circulation 1998;97:1675-1679
39. Laurila A, Bloigu A, Nayha S, Hassi J, Leinonen M, Saikku P. Association of Helicobacter pylori infection with elevated serum lipids. Atherosclerosis 1999;142:207-210
40. Kucukazman M, Yavuz B, Sacikara M, et al. The relationship between updated Sydney System score and LDL cholesterol levels in patients infected with Helicobacter pylori. Dig Dis Sci 2009;54:604-607
41. Takashima T, Adachi K, Kawamura A, et al. Cardiovascular risk factors in subjects with Helicobacter pylori infection. Helicobacter 2002;7:86-90.
42. Scragg RK, Fraser A, Metcalf PA. Helicobacter pylori seropositivity and cardiovascular risk factors in a multicultural workforce. J Epidemiol Community Health 1996;50:578-579
43. Hoffmeister A, Rothenbacher D, Bode G, et al. Current infection with Helicobacter pylori, but not seropositivity to Chlamydia pneumoniae or cytomegalovirus, is associated with an atherogenic, modified lipid profile. Arterioscler Thromb Vasc Biol 2001;21:427-432
44. Habara K, Hamada Y, Yamada M, et al. Pitavastatin up-regulates the induction of iNOS through enhanced stabilization of its mRNA in pro-inflammatory cytokine-stimulated hepatocytes. Nitric Oxide 2008;18:19-27.